Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammatory disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • Older

Inflammatory Disease Articles & Analysis

130 news found

Treating Acute Inflammatory Lung Disease: The Promise of Trimannose-Coupled Antimir-21

Treating Acute Inflammatory Lung Disease: The Promise of Trimannose-Coupled Antimir-21

Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. ...

BySCIREQ - an emka TECHNOLOGIES Company


CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

Therefore, flow cytometry is widely used in clinical diagnosis and medical research, such as tumor-associated diseases, autoimmune diseases, cardiovascular diseases, inflammatory infections and infectious diseases, providing higher clinical value for differential diagnosis, treatment monitoring and condition ...

ByCD Bioparticles


Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications

Creative BioMart Unveils Comprehensive Lectin Portfolio for Diverse Research Applications

Their versatility has propelled their adoption in various research pursuits, including the exploration of cancer, inflammatory processes, and infectious diseases. Moreover, lectins have garnered attention in the commercial sphere, paving the way for the development of diagnostic tools, therapeutic agents, and food additives. ...

ByCreative BioMart


Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic antibodies covering a wide range of diseases, including infectious diseases, cardiovascular diseases, cancer and bone diseases, especially osteoporosis. In addition, Creative Diagnostics possesses a variety of ...

ByCreative Diagnostics


Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution

This service intuitively studies the relationship between gut flora and disease development, providing new ideas for disease prevention and treatment and improving host health. ...

ByCreative Proteomics


Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. ...

ByAlfa Chemistry


Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence

Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence

The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. ...

ByIterative Health, Inc.


Built In Honors Iterative Health in Its Esteemed 2023 Best Places To Work Awards

Built In Honors Iterative Health in Its Esteemed 2023 Best Places To Work Awards

About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...

ByIterative Health, Inc.


Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery

Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. ...

BySuono Bio


Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence

Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence

This strategic partnership will lay the groundwork for future collaborations by using AIR to aid in the recruitment of patients for clinical trials in inflammatory bowel disease (IBD) and expanding Gastro Health’s clinical research capabilities. ...

ByIterative Health, Inc.


Iterative Health Named to the 2022 CB Insights’ Digital Health 150 List

Iterative Health Named to the 2022 CB Insights’ Digital Health 150 List

About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...

ByIterative Health, Inc.


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. ...

ByLumen Bioscience, Inc.


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

We are very pleased with today’s outcome as we continue our mission to improve lives of people living with inflammatory diseases.” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), ...

ByGalapagos NV


Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

To further streamline our portfolio, we have decided to discontinue activities in fibrosis and kidney disease to allow for increased investments in our oncology franchise. ...

ByGalapagos NV


Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Second, we will build on our current capabilities and derisk R&D through multiple drug modalities, including CAR-T, and by focusing on best-in-disease validated targets in our strategic therapeutic areas with shorter time-to-patient potential. ...

ByGalapagos NV


Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Endometriosis is an estrogen-driven, chronic inflammatory disease characterized by the presence of tissue resembling endometrium (the lining of the uterus) outside the uterus. ...

ByGesynta Pharma AB


Iterative Health Redefines Approach to Precision GI Care

Iterative Health Redefines Approach to Precision GI Care

AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are ...

ByIterative Health, Inc.


Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

T1D will form the pilot project for the program, but the goal is extend the functionality to other indications including other autoimmune diseases that are strongly linked to T1D such as celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland). ...

ByDiamyd Medical AB


Iterative Scopes Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUT

Iterative Scopes Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUT

About Iterative Scopes Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. ...

ByIterative Health, Inc.


Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...

ByAlnylam Pharmaceuticals, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT